ONE KENDALL SQUARE, CAMBRIDGE, MA
Investor Presentation
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Michael MacLean Appointed as Class III Director at CAMP4 Therapeutics
Material disclosure
CAMP4 Therapeutics Enters Underwriting Agreement for 5 Million Shares
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Free Writing Prospectus